RP14042
/ Rhizen, Incozen Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 03, 2022
Preclinical Profile of RP14042, a novel, selective, and potent smallmolecule inhibitor of PARP7
(AACR-NCI-EORTC 2022)
- "Data demonstrate the therapeutic potential of RP14042 inPARP7 overexpressing tumors"
Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma
1 to 1
Of
1
Go to page
1